PMID- 14624313
OWN - NLM
STAT- MEDLINE
DCOM- 20040519
LR  - 20240427
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 53
IP  - 5
DP  - 2004 May
TI  - Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
PG  - 391-403
AB  - PURPOSE: The carcinoembryonic antigen (CEA) is extensively expressed on the vast 
      majority of colorectal, gastric, and pancreatic carcinomas, and, therefore, is a 
      good target for tumor immunotherapy. CD4+ T-helper (Th) cells play a critical 
      role in initiation, regulation, and maintenance of immune responses. In this 
      study, we sought to identify Th epitopes derived from CEA which can induce 
      CEA-specific Th responses. The combined application with cytotoxic T lymphocyte 
      (CTL) epitopes would be more potent than tumor vaccines that primarily activate 
      CTL alone. METHODS: We utilized a combined approach of using a computer-based 
      algorithm analysis TEPITOPE and in vitro biological analysis to identify Th 
      epitopes in CEA. RESULTS: Initial screening of healthy donors showed that all 
      five predicted peptides derived from CEA could induce peptide-specific T-cell 
      proliferation in vitro. We characterized these CEA epitopes by establishing and 
      analyzing peptide-specific T-cell clones. It was shown that CD4+ T-cells specific 
      for the CEA(116 )epitope can recognize and respond to naturally processed CEA 
      protein and CEA(116 )epitope can be promiscuously presented by commonly found 
      major histocompatibility complex (MHC) alleles. Furthermore, it was demonstrated 
      that immunization of human leukocyte antigen (HLA)-DR4 transgenic mice with 
      CEA(116) peptide elicited antigen-specific Th responses which can recognize the 
      antigenic peptides derived from CEA protein and CEA-positive tumors. CONCLUSION: 
      The MHC class II-restricted epitope CEA(116) could be used in the design of 
      peptide-based tumor vaccine against several common cancers expressing CEA.
FAU - Shen, Lei
AU  - Shen L
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, 
      Alkek Bldg. N1004, Houston, TX 77030, USA.
FAU - Schroers, Roland
AU  - Schroers R
FAU - Hammer, Juergen
AU  - Hammer J
FAU - Huang, Xue F
AU  - Huang XF
FAU - Chen, Si-Yi
AU  - Chen SY
LA  - eng
GR  - R01 AI048711/AI/NIAID NIH HHS/United States
GR  - AI48711/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20031118
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-DR4 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Carcinoembryonic Antigen/*immunology
MH  - Cell Division
MH  - Dendritic Cells/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epitope Mapping
MH  - Epitopes, T-Lymphocyte/genetics/*immunology
MH  - Genes, MHC Class II/*immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/immunology/metabolism
MH  - HLA-DR4 Antigen/genetics/*immunology
MH  - Humans
MH  - Immunization
MH  - Interferon-gamma/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Peptide Fragments/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Helper-Inducer/*immunology
MH  - Tumor Cells, Cultured
PMC - PMC11034193
EDAT- 2003/11/19 05:00
MHDA- 2004/05/20 05:00
PMCR- 2003/11/18
CRDT- 2003/11/19 05:00
PHST- 2003/06/09 00:00 [received]
PHST- 2003/09/03 00:00 [accepted]
PHST- 2003/11/19 05:00 [pubmed]
PHST- 2004/05/20 05:00 [medline]
PHST- 2003/11/19 05:00 [entrez]
PHST- 2003/11/18 00:00 [pmc-release]
AID - 455 [pii]
AID - 10.1007/s00262-003-0455-y [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2004 May;53(5):391-403. doi: 
      10.1007/s00262-003-0455-y. Epub 2003 Nov 18.